Is It Post-Finasteride Syndrome Or Testosterone And Anxiety?
Timeline
Timestamp
Topic
00:00
A 27-year-old man describes topical finasteride use, severe panic and anxiety, subsequent DHT gel use, testosterone therapy, treatment-center care, and his question about whether he actually developed post-finasteride syndrome.
03:17
Dr. O’Connor begins explaining post-finasteride syndrome, describes it as rare, and contrasts systemic oral finasteride with the smaller systemic exposure expected from topical finasteride.
05:27
Finasteride, dutasteride, DHT, male-pattern hair loss, and benign prostatic hyperplasia are reviewed, including why suppressing DHT can also produce effects outside the hair follicle.
07:44
Dr. O’Connor says the member’s brief topical finasteride exposure does not appear to explain the entire clinical picture and discusses how testosterone can exacerbate underlying anxiety and mood disorders in some men.
08:58
Because the anxiety became severe enough to require treatment, Dr. O’Connor stresses the need for qualified psychiatric care and discusses seeking clinicians who also understand testosterone therapy.
12:35
Dr. O’Connor closes by emphasizing ongoing mental health care along with ABCDs™ monitoring, including blood pressure, A1C, diabetes risk, cholesterol, and cardiovascular health if testosterone use continues.
Video Summary
A 27-year-old man describes severe anxiety and panic attacks that began around a period of topical finasteride use for hair loss. After stopping the topical medication, he initially felt substantially better, but continued reading about post-finasteride syndrome and later tried DHT gel, after which he experienced major anxiety and panic severe enough to interfere with his job and require treatment at a mental health facility. He was already using testosterone and is now taking a low-dose SSRI.
Dr. Thomas O’Connor reviews the history and explains why he does not believe the presentation clearly fits post-finasteride syndrome. He distinguishes topical finasteride from oral finasteride, discusses systemic exposure, DHT suppression, finasteride and dutasteride, male-pattern hair loss, and the use of these drugs for benign prostatic hyperplasia.
A major focus is the interaction between testosterone and mental health. Dr. O’Connor explains that testosterone can exacerbate underlying anxiety and mood disorders in some men and strongly emphasizes the importance of working with qualified psychiatric healthcare professionals. He closes by encouraging continued mental health care while also monitoring the ABCDs™, including blood pressure, A1C, diabetes risk, and cardiovascular health if testosterone use continues.
Drug Callouts
Drug
Description
Finasteride
Finasteride is central to the member’s concern about post-finasteride syndrome. Dr. O’Connor describes it as a DHT-blocking medication used orally for hair loss and benign prostatic hyperplasia and explains that topical finasteride generally produces less systemic exposure than the oral form.
Testosterone
The member was already using testosterone during the period in which his anxiety and panic developed. Dr. O’Connor says testosterone can exacerbate underlying anxiety and mood disorders in some men and believes that possibility deserves consideration in this case.
Dihydrotestosterone (DHT) Gel
The member reports trying DHT gel while attempting to correct what he believed was post-finasteride syndrome and says he subsequently experienced major anxiety and panic. Dr. O’Connor discusses DHT extensively in relation to finasteride, hair follicles, the prostate, and central nervous system effects.
Dutasteride
Dutasteride is discussed as another DHT-blocking medication. Dr. O’Connor describes it as a more powerful blocker than finasteride that affects type 1 and type 2 pathways and is primarily used for enlarged prostate rather than hair loss.
Condition Callouts
Condition
Description
Post-Finasteride Syndrome
Post-finasteride syndrome is the member’s primary concern after experiencing severe anxiety following topical finasteride exposure. Dr. O’Connor describes the syndrome as rare and says this particular history does not clearly fit the pattern he associates with persistent problems after finasteride, especially because the member used a topical preparation and was also taking testosterone.
Panic Attacks and Anxiety
Severe panic attacks and anxiety are the dominant symptoms in this case and eventually became serious enough to interfere with the member’s work and require treatment. Dr. O’Connor emphasizes that men using testosterone can experience worsening of pre-existing anxiety and that psychiatric evaluation is important when symptoms become this severe.
Mood Disorders
Dr. O’Connor raises the possibility that an underlying mood disorder may be contributing more to the member’s symptoms than topical finasteride. In men using testosterone, he stresses the importance of recognizing underlying psychiatric conditions because androgen exposure may aggravate mood symptoms in susceptible individuals.
Male-Pattern Hair Loss
The member originally used topical medications because of hair loss concerns. Dr. O’Connor explains the relationship between DHT-sensitive scalp hair follicles and medications such as finasteride, while also discussing the tradeoff between suppressing DHT and potential effects elsewhere in the body.
The member originally used topical medications because of hair loss concerns. Dr. O’Connor explains the relationship between DHT-sensitive scalp hair follicles and medications such as finasteride, while also discussing the tradeoff between suppressing DHT and potential effects elsewhere in the body.
Dr. O’Connor discusses BPH while explaining the medical uses of finasteride and dutasteride. Because DHT influences prostate tissue, medications that reduce DHT activity can shrink an enlarged prostate, an issue that can also be relevant when monitoring prostate health in men using testosterone.
Hypertension
Blood pressure is included in Dr. O’Connor’s closing ABCDs™ discussion. For a man who remains on testosterone, he emphasizes continued blood pressure monitoring as part of protecting long-term cardiovascular health rather than focusing exclusively on hormone levels or the current anxiety symptoms.
Key Takeaways
- Dr. O’Connor does not believe the member’s history clearly supports post-finasteride syndrome, particularly given the brief topical exposure and improvement after stopping it.
- Topical and oral finasteride should not automatically be treated as equivalent because Dr. O’Connor emphasizes that topical use generally results in substantially less systemic exposure.
- The member was already using testosterone, and Dr. O’Connor considers testosterone-related worsening of an underlying anxiety or mood disorder an important possibility.
- Trying additional hormonal interventions such as DHT gel in an attempt to correct suspected post-finasteride syndrome did not help this member and was followed by severe anxiety and panic.
- When anxiety becomes severe enough to disrupt work or require treatment-center care, Dr. O’Connor stresses the need for qualified psychiatric professionals rather than trying to manage the problem only through hormone adjustments.
- Mental health treatment should occur alongside broader health monitoring for men on testosterone, including the ABCDs™, blood pressure, A1C, diabetes risk, cholesterol, and cardiovascular health.